RT Journal Article
T1 Liver manifestations in COVID-19 and the influence of pre-existing liver disease in the course of the infection
A1 Guerra Veloz, María Fernanda
A1 Cordero Ruiz, Patricia
A1 Ríos-Villegas, María José
A1 Del Pino Bellido, Pilar
A1 Bravo-Ferrer, José
A1 Galvés Cordero, Rocío
A1 Cadena Herrera, María Lorena
A1 Vías Parrado, Carmen
A1 Bellido Muñoz, Francisco
A1 Vega Rodríguez, Francisco
A1 Caunedo Álvarez, Ángel
A1 Rodríguez-Baño, Jesús
A1 Carmona Soria, Isabel
K1 SARS-CoV-2
K1 Chronic liver disease
K1 Advanced fibrosis
K1 Hospital admission rate
K1 Mortality
K1 Hepatopatía terminal
K1 Fibrosis
K1 Pruebas de admisón rutinarias
K1 Mortalidad
AB Introduction: patients with advanced chronic liver disease (CLD) may be at an increased risk of a severe course due to cirrhosis-associated immune dysfunction. The aim of this study was to determine the prevalence of CLD in COVID-19 patients and to analyze the course of the infection, com pared with patients with non-liver disease. Materials and methods: this was a retrospective single cen ter study of all patients with a positive SARS-CoV-2 poly merase chain reaction (PCR) test from March 23rd to April 30th, 2020. Clinical and biochemical data of patients with and without CLD and COVID-19 were collected from the medical records. Result: four hundred and forty-seven patients with a SARS CoV-2 positive PCR were included, 6.3 % had CLD; 69.7 % of patients with CLD were male, with a median age of 65.5 years and active alcohol consumption and smoking; 75 % had non-advanced liver fibrosis and most had non-alcoholic fatty liver disease (NAFLD). The hospital admission rate (92.9 % vs 47.7 %, p < 0.001), concomitant comorbidities (diabetes 38.5 vs 16.5 %, p = 0.011; obesity 30.8 vs 8.5 %, p = 0.033; cancer 23.1 vs 5 %, p = 0.027; and chronic obstructive pulmonary disease (COPD) 19.2 vs 9 %, p = 0.009) and con comitant antibiotics treatment (19.3 vs 5 %, p = 0.018) were higher in patients with CLD than in those without CLD. In patient hospital mortality rates were similar in both groups (30.8 vs 19.6 %, p = 0.289). The presence of CLD was not associated with mortality (OR = 1.06; 95 % CI = 0.35-3.18; p = 0.924). However, patients with CLD and COVID-19 who were male, obese or under concomitant antibiotic treat ment had the highest risk of mortality according to the uni variate analysis. Conclusion: patients with CLD had a higher risk of hospi tal admission, with worse outcomes during the COVID-19 infection associated to other concomitant comorbidities and a suspicion of bacterial co-infection.
PB Sociedad Española de Patologia Digestiva
SN 1130-0108
YR 2021
FD 2021
LK http://hdl.handle.net/10668/3957
UL http://hdl.handle.net/10668/3957
LA en
NO Guerra Veloz MF, Cordero Ruiz P, Ríos-Villegas MJ, Del Pino Bellido P, Bravo-Ferrer J, Galvés Cordero R, et al. Liver manifestations in COVID-19 and the influence of pre-existing liver disease in the course of the infection. Rev Esp Enferm Dig. 2021 Feb;113(2):103-109
DS RISalud
RD Apr 4, 2025